The Senate calling into question the 340B Drug Pricing Program

The United States Senate Committee on Health, Education, Labor and Pensions (HELP) is calling into question the intent of 340B Drug Pricing Program in hearing on Tuesday. The hearing coincided with the release of a Government Accountability Office report that found Health Resources and Services Administration (HRSA) lack of oversight of the program. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.